Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 44, Issue 5, 2005, Pages 428-433

  Ratner, Sharon ^a   Laor, Nathaniel ^a,c,d   Bronstein, Yifat ^a   Weizman, Abraham ^b,c   Toren, Paz ^a,c,e  

^a Tel Aviv Brull Comm Mental Hlth C   (Israel)

^b GEHA MENTAL HEALTH CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE   (Israel)

Author keywords

Anxiety symptoms; Attention deficit hyperactivity disorder; Depressive symptoms; Reboxetine

Indexed keywords

METHYLPHENIDATE; REBOXETINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGGRESSION; AGITATION; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MALE; MUSCLE WEAKNESS; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEDATION; SIDE EFFECT; SLEEP DISORDER;

EID: 17644396018     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000155327.30017.8c     Document Type: Article

References (38)

1. American Psychiatric Association (2000), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV-TR). Washington, DC: American Psychiatric Association
2. Banaschewski T, Roessner V, Dittmann RW, Janardhanan Santosh P, Rothenberger A (2004), Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13(suppl 1):I102-I116
3. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS (1989), A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777-784
4. Biederman J, Faraone S, Milberger S et al. (1996), A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 53:437-446
5. Biederman J, Heiligenstein JH, Faries DE et al., Atomoxetine ADHD Study Group (2002), Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics 110:e75
6. Biederman J, Spencer T (1999), Attention deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234-1242
7. Biederman J, Spencer T, Wilens T (2004), Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 7:77-97
8. Bymaster FP, Katner JS, Nelson DL et al. (2002), Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711
9. Conners CK, Barkley RA (1985), Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull 21:809-843
10. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998), ADHD Rating Scale IV: Checklists, Norms, and Clinical Interpretation. New York: Guilford.
11. Edwards DM, Pellizzoni C, Breuel HP et al. (1995), Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 16:443-460
12. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L (1985), Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 25:296-301
13. Fischer M, Barkley RA, Smallish L, Fletcher K (2002), Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 30:463-475
14. Greenhill LL (1992), Pharmacologic treatment of attention-deficit disorder. Psychiatr Clin North Am 15:1-25
15. Guy W (1976), ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: U.S. Department of Health, Education, and Welfare
16. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH (2004), The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10:23-44
17. Hansen C, Weiss D, Last CG (1999), ADHD boys in young adulthood: psychosocial adjustment. J Am Acad Child Adolesc Psychiatry 38:165-171
18. Kent JM (2000), SNaRIs, NaSSAs, and NaRIs: new agents for treatment of depression. Lancet 355:911-918
19. Kovacs M (1985), The Children's Depression Inventory. Psychopharmacol Bull 21:995-998
20. Kratochvil CJ, Heiligenstein JH, Dittmann R et al. (2002), Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41:776-784
21. Labellarte MJ, Crosson JE, Riddle MA (2003), The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 42:642-650
22. Michelson D, Allen AJ, Busner J et al. (2002), Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901
23. Michelson D, Faries D, Wernicke J et al., Atomoxetine ADHD Study Group (2001), Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83
24. Montgomery SA (1989), Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 59:26-29
25. Otka JE, Mercadante MT, Scahill L, Leckman JF (2001), Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder [letter to the editor]. J Child Adolesc Psychopharmacol 11:203-204
26. Pliszka SR (2003), Psychiatric comorbidities in children with attention deficit hyperactivity disorder: implications for management. Paediatr Drugs 5:741-750
27. Pliszka SR, McCracken JT, Maas JW (1996), Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 35:264-272
28. Reynolds CR, Richmond BO (1997), What I think and feel: a revised measure of children's manifest anxiety. J Abnorm Child Psychol 25:15-20
29. Reynolds CR, Richmond BO (1985), Manual for the Revised Children's Manifest Anxiety Scale. Los Angeles: Western Psychological Services
30. Shanee N, Apter A, Weizman A (1997), Psychometric properties of the K-SADS-PL in an Israeli adolescent clinical population. Isr J Psychiatry Relat Sci 34:179-187
31. Spencer T, Biederman J, Coffey B et al. (2002a), A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 59:649-656
32. Spencer T, Biederman J, Heiligenstein J et al. (2001), An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:251-265
33. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S (1996), Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409-432
34. Spencer T, Heiligenstein JH, Biederman J et al. (2002b), Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140-1147
35. Spivak B, Vered Y, Yoran-Hagesh R et al. (1999), Circulatory levels of catecholamines, serotonin and lipids in attention deficit hyperactivity disorder. Acta Psychiatr Scand 99:300-304
36. Valentini V, Frau R, Di Chiara G (2004), Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J Neurochem 88:917-927
37. Walkup JT, Labellarte MJ, Riddle MA et al. (2001), Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279-1285
38. Weiss M, Weiss G (1996), Attention deficit hyperactivity disorder. In: Child and Adolescent Psychiatry, Lewis M, ed. Baltimore: Williams & Wilkins, pp 645-670